Hypertensive disorders of pregnancy, including preeclampsia, complicate up to 10% of pregnancies worldwide, constituting one of the greatest causes of maternal and perinatal morbidity and mortality worldwide. The aim of the current study is to evaluate the efficacy of omega-3 supplements in prevention of preeclampsia among women with high risk. This study was carried out at Shanroy Hospital in al –Sulaimanya city from January 2016 till December 2016.In a single blind clinical trial, a total of 100 pregnant women were divided into two groups, one group had received omega-3 1000 mg and another group receive capsule prefilled with glucose as placebo. Selection criteria include: primipara women, ages under than 20 and above 40 years, previous history of preeclampsia or positive family history, obesity, history of renal disease and hypertension. Demographic profile with pregnancy length and neonatal outcome were recorded. The result of this study showed there was significant difference in development of preeclampsia during current pregnancy between omega-3 and placebo groups and there was a significant relationship (p<0.05) between both groups when compare the preeclampsia   in its all forms. In conclusion, omega-3 deems promising drug for prevention of preeclampsia in pregnant women with high risk.

Hypertensive disorders of pregnancy, including preeclampsia, complicate up to 10% of pregnancies worldwide, constituting one of the greatest causes of maternal and perinatal morbidity and mortality worldwide. The aim of the current study is to evaluate the efficacy of omega-3 supplements in prevention of preeclampsia among women with high risk. This study was carried out at Shanroy Hospital in al -Sulaimanya city from January 2016 till December 2016.In a single blind clinical trial, a total of 100 pregnant women were divided into two groups, one group had received omega-3 1000 mg and another group receive capsule prefilled with glucose as placebo. Selection criteria include: primipara women, ages under than 20 and above 40 years, previous history of preeclampsia or positive family history, obesity, history of renal disease and hypertension. Demographic profile with pregnancy length and neonatal outcome were recorded. The result of this study showed there was significant difference in development of preeclampsia during current pregnancy between omega-3 and placebo groups and there was a significant relationship (p<0.05) between both groups when compare the preeclampsia in its all forms. In conclusion, omega-3 deems promising drug for prevention of preeclampsia in pregnant women with high risk.